Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma

Liver International

Volumn 30, Issue 1, 2010, Pages 65-75

  Hui, Ivan Chun Fai ^a   Tung, Edmund Kwok Kwan ^a   Sze, Karen Man Fong ^a   Ching, Yick Pang ^a   Ng, Irene Oi Lin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CCI 779; Hepatocellular carcinoma; mTOR; p70S6K; Rapamycin; Tumour suppression

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S6 KINASE; TEMSIROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL COUNT; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 73349090909     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02117.x     Document Type: Article

References (47)

1. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807-26.
2. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-45.
3. Law B.K. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005; 56: 47-60.
4. Ma XM, Blenis J. Molecular mechanisms of mTORmediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-18.
5. Bjornsti MA, Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-48.
6. Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231-5.
7. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-8.
8. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder S.H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35-43.
9. Brunn GJ, Williams J, Sabers C, et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996; 15: 5256-67.
10. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277: 99-101.
11. Withers DJ, Ouwens DM, Nave BT, et al. Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. Biochem Biophys Res Commun 1997; 241: 704-9.
12. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998; 95: 1432-7.
13. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570-3.
14. Law BK, Chytil A, Dumont N, et al. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 2002; 22: 8184-98.
15. Barata JT, Cardoso AA, Nadler LM, Boussiotis VA, et al. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by downregulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 2001; 98: 1524-31.
16. Easton JB, Houghton P.J. mTOR and cancer therapy. Oncogene 2006; 25: 6436-46.
17. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-58.
18. Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004; 104: 4181-7.
19. Asano T, Yao Y, Zho J, et al. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun 2005; 331: 295-302.
20. Wu L, Birle DC, Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825-31.
21. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
22. Chollet P, Abrial C, Tacca O, et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006; 7: 336-8.
23. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
24. Shah SA, Wei AC, Cleary SP, et al. Prognosis and results after resection of very large (4or = 10 cm) hepatocellular carcinoma. J Gastrointest Surg 2007; 11: 589-95.
25. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988; 207: 373-9.
26. Ng IO, Lai EC, Fan ST, Ng MM, So M.K. Prognostic significance of pathologic features of hepatocellular carcinoma A multivariate analysis of 278 patients. Cancer 1995; 76: 2443-8.
27. Peng T, Golub TR, Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002; 22: 5575-84.
28. Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-5.
29. Chen JS, Wang Q, Fu XH, et al. Involvement of PI3K/ PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 2009; 39: 177-86.
30. Baba HA, Wohlschlaeger J, Cicinnati VR, et al. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int 2009; 29: 399-405.
31. Wang Z, Fan J, Zhou J, et al. Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: experiment with mice. Zhonghua Yi Xue Za Zhi 2006; 86: 1666-70.
32. Chiang GG, Abraham R.T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005; 280: 25485-90.
33. Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 2005; 280: 26089-93.
34. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-14.
35. Yu Y, Sato J.D. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999; 178: 235-46.
36. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/ AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5.
37. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767-75.
38. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002; 277: 27975-81.
39. Lee L., Sudentas P, Dabora S.L. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer 2006; 45: 933-44.
40. Amornphimoltham P, Patel V, Sodhi A, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005; 65: 9953-61.
41. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/ P.K.B. Mol Cell 2006; 22: 159-68.
42. Ito D, Fujimoto K,Mori T, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 2006; 118: 2337-43.
43. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-8.
44. Sarbassov DD, Guertin DA, Ali SM, Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science 2005; 307: 1098-101.
45. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420: 629-35.
46. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004; 16: 564-75.
47. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004; 91: 1420-4.